Article Data

  • Views 1119
  • Dowloads 168

Short Communication

Open Access Special Issue

A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer

  • Szigeti András1
  • Kocsis Károly1
  • Ambrus Adél1
  • Kránitz Noémi2
  • Szepesváry Zsolt3
  • Kullmann Tamás1,*,

1Department of Oncoradiology, Petz Aladár Hospital, 9024 Győr, Hungary

2Department of Pathology, Petz Aladár Hospital, 9024 Győr, Hungary

3Department of Urology, Petz Aladár Hospital, 9024 Győr, Hungary

DOI: 10.31083/jomh.2021.133 Vol.18,Issue 2,February 2022 pp.1-4

Submitted: 01 September 2021 Accepted: 23 September 2021

Published: 28 February 2022

(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)

*Corresponding Author(s): Kullmann Tamás E-mail:


Background: The sensitivity and specificity of bone scintigraphy and thoraco-abdominopelvic CT scans traditionally used for the staging of prostate cancer don't meet clinical requirements. In 2020 18F-JK-PSMA-7 positron emission tomography-computed tomography (PET-CT) became available in our country for routine clinical diagnostics.

Methods: As part of our self-assessment, we retrospectively analysed the results of 24 PSMA PET-CTs realised for our patients up to 31 December 2020.

Results: The indication of the examination was biochemical recurrence after radical prostatectomy (prostate specific antigen (PSA) >0.2 ng/mL) for 16 patients and primary staging (PSA range: 5.2–70 ng/mL) for 8 patients. Biochemical recurrence was related to local relapse in 2 cases, regional lymph node involvement in 5 cases, oligo- and multi-metastatic spread in 1 and 3 cases respectively. 5 patients had no detectable lesion. Patients with PSA <1 ng/mL showed no extrapelvic enhancement. At primary staging 3 patients presented distant metastases. There was no correlation between PSA level and disease extent. In total PSMA PET-CT results changed the treatment strategy for 7 patients.

Conclusions: 18F-JK-PSMA-7 PET-CT is a useful diagnostic tool. The examination can lead to change the treatment decision at primary staging as well as at biochemical recurrence. The results of this pilot study may support the strategy that patients with biochemical recurrence following radical prostatectomy receive salvage radiotherapy to the prostate bed and the pelvic lymphatic regions without any imaging examination when PSA <1 ng/mL.


Prostate cancer; PSMA PET-CT; Biochemical relapse; Therapy optimisation

Cite and Share

Szigeti András,Kocsis Károly,Ambrus Adél,Kránitz Noémi,Szepesváry Zsolt,Kullmann Tamás. A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer. Journal of Men's Health. 2022. 18(2);1-4.


[1] Grubmüller B, Baum RP, Capasso E, Singh A, Ahmadi Y, Knoll P, et al. 64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: first in-Human Studies. Cancer Biotherapy and Radiopharmaceuticals. 2016; 31: 277–286.

[2] Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence after Radical Prostatectomy. Journal of Nuclear Medicine. 2015; 56: 668–674.

[3] Tateishi U. Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Japanese Journal of Clinical Oncology. 2020; 50: 349–356.

[4] Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, et al. An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: first-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 during the first Year of Application. Journal of Nuclear Medicine. 2020; 61: 202–209.

[5] Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients who have Rising PSA after Curative Treatment and are being Considered for Targeted Therapy. Journal of Nuclear Medicine. 2015; 56: 1185–1190.

[6] Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent–update 2013. European Urology. 2014; 65: 124–137.

[7] Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology. 2019; 1: 531–537.

[8] Kimura S, Abufaraj M, Janisch F, Iwata T, Parizi MK, Foerster B, et al. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases. 2020; 23: 1-10.

[9] Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: a Systematic Review and Meta-analysis. European Urology. 2017; 70: 926–937.

[10] Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. The Lancet Oncology. 2019; 20: 1286–1294.

[11] Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet. 2020; 395: 1208–1216.

[12] Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology. 2018; 71: 618–629.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Directory of Open Access Journals (DOAJ) DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.

SCImago The SCImago Journal & Country Rank is a publicly available portal that includes the journals and country scientific indicators developed from the information contained in the Scopus® database (Elsevier B.V.)

Publication Forum - JUFO (Federation of Finnish Learned Societies) Publication Forum is a classification of publication channels created by the Finnish scientific community to support the quality assessment of academic research.

Scopus: CiteScore 0.7 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Norwegian Register for Scientific Journals, Series and Publishers Search for publication channels (journals, series and publishers) in the Norwegian Register for Scientific Journals, Series and Publishers to see if they are considered as scientific. (

Submission Turnaround Time